
Person—fibrinolytic therapy status, code NN



This product, excluding the AlHW logo, Commonwealth Coat of Arms and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY 4.0 (CC BY 4.0) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures. We have made all reasonable efforts to identify and label material owned by third parties.

You may distribute, remix and build on this website's material but must attribute the AlHW as the copyright holder, in line with our attribution policy. The full terms and conditions of this licence are available at https://creativecommons.org/licenses/by/4.0/.

Enquiries relating to copyright should be addressed to info@aihw.gov.au.

Enquiries or comments on the METEOR metadata or download should be directed to the METEOR team at meteor@aihw.gov.au.

Person—fibrinolytic therapy status, code NN

Identifying and definitional attributes

Metadata item type: Data Element

Short name: Fibrinolytic therapy status

METEOR identifier: 285087

Registration status: Health, Standard 04/06/2004

Definition: The person's fibrinolytic therapy status, as represented by a code.

 Data Element Concept:
 Person—fibrinolytic therapy status

 Value Domain:
 Fibrinolytic therapy status code NN

Value domain attributes

Representational attributes

Representation class:	Code	
Data type:	Number	
Format:	NN	
Maximum character length:	2	
	Value	Meaning
Permissible values:	10	Given
	21	Not given - therapy not indicated
	22	Not given - patient refusal
	23	Not given - previous haemorrhagic stroke at any time; other strokes or cerebrovascular events within 1 year
	24	Not given - known intracranial neoplasm
	25	Not given - active or recent (within 2 to 4 weeks) internal bleeding (does not include menses)
	26	Not given - suspected aortic dissection
	27	Not given - severe uncontrolled hypertension on presentation (blood pressure >180 mmHg systolic and/or 110 mmHg diastolic). Note: This could be an absolute contraindication in low-risk patients with MI.
	28	Not given - history of prior cerebrovascular accident or known intracerebral pathology not covered in 2.3 & 2.4 contraindications
	29	Not given - current use of anticoagulants in therapeutic doses (INR greater than or equal to 2); known bleeding diathesis
	30	Not given - recent trauma (within 2 to 4 weeks), including head trauma, traumatic or prolonged (greater than 10 minutes) CPR, or major surgery (less than 3 weeks)
	31	Not given - pregnancy
	32	Not given - other
Supplementary values:	90	Not stated/inadequately described

Source and reference attributes

Submitting organisation: Australian Institute of Health and Welfare

Data element attributes

Collection and usage attributes

Guide for use: CODES 23, 24, 25, 26, 27, 28, 29, 30 and 31

More than one code may be recorded for the following codes: 23, 24, 25, 26, 27,

28, 29, 30 and 31,

Source and reference attributes

Submitting organisation: Acute coronary syndrome data working group

The National Heart Foundation of Australia and The Cardiac Society of Australia Steward:

and New Zealand

Relational attributes

Related metadata references:

Is re-engineered from Fibrinolytic therapy status, version 1, DE, NHDD, NHIMG,

Superseded 01/03/2005.pdf (17.0 KB)

No registration status

Specifications:

Health, Superseded 01/10/2008

DSS specific information:

For Acute coronary syndrome (ACS) reporting, to be collected with the data elements Triage—triage date, DDMMYYYY, Triage—triage time, hhmm, Person risk stratum, code N.

This data element pertains to the administering of fibrinolytic therapy drugs at any time point during this current event.

Acute coronary syndrome (clinical) DSS Health, Superseded 07/12/2005

DSS specific information:

For Acute coronary syndrome (ACS) reporting, to be collected with the data elements Triage—triage date, DDMMYYYY, Triage—triage time, hhmm, Person risk stratum, code N.

This data element pertains to the administering of fibrinolytic therapy drugs at any time point during this current event.